Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients

Strahlentherapie und Onkologie

Volumn 187, Issue 3, 2011, Pages 158-166

  Souchon, Rainer ^a   Hartmann, Michael ^b   Krege, Susanne ^c   Lorch, Anja ^d   Mayer, Frank ^a   De Santis, Maria ^e   Gillessen, Silke ^f   Beyer, Jörg ^g   Cathomas, Richard ^h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Krankenhaus Maria Hilf   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g VIVANTES KLINIKUM AM URBAN   (Germany)

^h Medical Oncology   (Switzerland)

Author keywords

Follow up; Radiotherapy; Recommendations; Seminoma; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CREATININE; FLUORODEOXYGLUCOSE F 18; FOLLITROPIN; LACTATE DEHYDROGENASE; LIPID; LUTEINIZING HORMONE; TESTOSTERONE; ANTINEOPLASTIC AGENT;

ABDOMINAL RADIOGRAPHY; BLOOD PRESSURE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CARCINOMA IN SITU; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; GERM CELL TUMOR; HUMAN; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR; SEMINOMA; TESTICULAR INTRAEPITHELIAL NEOPLASIA; TESTIS BIOPSY; TESTIS NONSEMINOMA CANCER; THORAX RADIOGRAPHY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL PATHWAY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; COOPERATION; DISEASE COURSE; IMAGE PROCESSING; INTERDISCIPLINARY COMMUNICATION; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT CARE; RADIATION INDUCED NEOPLASM; SECOND CANCER; SENSITIVITY AND SPECIFICITY; TESTIS TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; CRITICAL PATHWAYS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERDISCIPLINARY COMMUNICATION; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PATIENT CARE TEAM; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 79955649633     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2227-x     Document Type: Review

References (43)

1. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. EAU European Association of Urology 2009. Eur Urol 2005;48:885-94.
2. American Society of Clinical Oncology Guideline Procedures Manual (December 2006). Expert Panel Version 2.0. Alexandria, VA: ASCO (http://www.asco.org).
3. Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009;169:2071-7.
4. Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004;232:735-8. (Pubitemid 39100257)
5. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. (Pubitemid 350190758)
6. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 2007;25:1033-7. (Pubitemid 46596752)
7. Cathomas R, Helbling D, Stenner F, et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkl 2010;140:356-69
8. Claßen J, Schmidberger H, Meisner C, et al. Radiotherapy for stage IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101-6. (Pubitemid 46594140)
9. Classen J, Schmidberger H, Souchon R, et al. What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy? Strahlenther Onkol 2009;185:349-54.
10. Classen J. Radiotherapie oder Chemotherapie beim reinen Seminom im Stadium IIA und IIB? Strahlenther Onkol 2009;185:611-3.
11. Classen J, Souchon R, Hehr T, et al. Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis. J Cancer Res Clin Oncol 2010;136:227-32.
12. Dalal PU, Sohaib, SA, Huddart R. Imaging of testicular germ cell tumors. Cancer Imaging 2006;6:124-34.
13. Damgaard-Pedersen K, von der Maase H. Ultrasound and ultrasound guided biopsy, CT and lymphography in the diagnosis of retroperitoneal metastases in testicular cancer. Scand J Urol Nephrol Suppl. 1991;137:139-44.
14. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9. (Pubitemid 41095035)
15. De Santis M, Strau G, and Bachner M. Cross-sectional imaging techniques: the use of computed tomography (CT) and magnetic resonance imaging (MRI) in the management of germ cell tumors. In: de la Rosette JMCH, Manyak MJ, Harisinghani MG, Wijkstra H (eds) Imaging in Oncological Urology. Springer Verlag, Berlin 2009, chapter 27, 287.
16. Dieckmann KP, Souchon R, Hahn E, et al. False-negative biopsies for testicular intraepithelial neoplasia. J Urol 1999;162:364-8. (Pubitemid 29434342)
17. Dieckmann KP, Lauke H, Michl U, et al. Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur Urol 2002;41:643-9.
18. Eich HT. Langzeitnebenwirkungen nach Hochdosis-Chemotherapie und Radiotherapie bei Patienten mit rezidivierten oder refraktären HodgkinLymphomen. Strahlenther Onkol 2009;185:541-2.
19. Fossa SD. Long-term sequelae after cancer therapy - survivorship after treatment for testicular cancer. Acta Oncol 2004;43:134-41. (Pubitemid 38478899)
20. Gilligan TD, Seidenfeld J, Basch EM et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010;28:3388-404.
21. Harvey ML, Geldart TR, Duell R, et al. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer - a necessary risk? Ann Oncol 2002;13:237-42. (Pubitemid 34704975)
22. Haugnes HS, Aass N, Fossa SD, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2008;2:128-37.
23. International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 1997;15: 594-603.
24. Krege S, Beyer J, Souchon R, et al. European Consensus Conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG). Part I and II. Eur Urol 2008;53:478-96 and 497-513.
25. Martin JM, Panzarella T, Zwahlen DR, et al. Evidence-based guidelines for following stage 1 seminoma. Cancer 2007;109:2248-56. (Pubitemid 46801554)
26. Mead GM, Fossa SD, Oliver RT, et al. Relapse patterns in 2.466 stage I seminoma patients entered into Medical Research Council randomised trials. J Clin Oncol 2008;26(suppl):5020.
27. Mezvrishvili Z, Tchanturaia Z, Toidze T, et al. Is ultrasound of the retroperitoneum a valuable staging method in selecting testicular cancer patients for primary retroperitoneal lymph node dissection? Urol Int 2007;78:226-9. (Pubitemid 46524951)
28. Nuver J, Smit AJ, Wolffenbuttel BHR, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718-25.
29. Schmoll HJ, Souchon R, Krege S, et al. European Consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99. (Pubitemid 39295027)
30. Schmoll HJ, Jordan K, Huddart R, et al. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2010;21(Suppl 5):140-6.
31. Schmoll HJ, Jordan K, Huddart R, et al. Testicular non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow. Ann Oncol 2010;21(Suppl 5):147-54.
32. Shinn EH, Swartz RJ, Thornton BB, et al. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol 2010;28:2274-9.
33. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated attributable risk of cancer. Arch Intern Med 2009;169:2078-86.
34. Souchon R, Schmoll HJ, Krege S, Heidenreich A. Leitlinie zur Diagnostik und Therapie von Hodentumoren auf Grundlage evidenzbasierter Medizin: German Testicular Cancer Study Group. Zuckschwerdt Verlag 2002.
35. Testicular Cancer. NCCN National Comprehensive Cancer Network, version 2007 (http://www.nccn.org/professionals/physidan-gls/f-guidelines.asp).
36. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40.576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65. (Pubitemid 41487803)
37. TRISST (MRC TE24) Trial of imaging and schedule in seminoma testis (http://www.ctu.mrc.ac.uk/studies/TE24.asp).
38. van As NJ, Gilbert DC, Money-Kyrle J, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008;98:1894-902. (Pubitemid 351821555)
39. Van den Belt-Dusebout A, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-8. (Pubitemid 350013842)
40. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52. (Pubitemid 35334756)
41. White PM, Howard GCW, Best JJK, Wright AR. The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumors. Clin Radiol 1997;52:124-9.
42. Willich N, Ernst I, Pape H, et al. Evaluation of side effects after radiotherapy in childhood and adolescence: from retrospective case reports to a prospective, multicentric and transnational approach. Strahlenther Onkol 2009;185(Suppl 2):3-4.
43. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010;4:E19-38.